Why Greenfire
How we build success
Medical innovations are precious and exciting and come from all over. Making a good idea in medicine into a product is a difficult and expensive process. It requires expertise and capital often not available for startups completing laboratory proof-of-concept.
That’s where Greenfire comes in. We have assembled experts, advisors, service providers, and capital to deploy on late pre-clinical and early clinical assets to accelerate their development into products.
Our extensive network seeks out exciting innovations, engages flexibly with the innovators, and accelerates the transition to medical products. We take the unappreciated risks out of development – timely access to expertise and capital. If you think you have an innovation that fits our profile, contact us.
And when a product is ready for the last steps for approval and commercialization, our team has deep experience in navigating the right path to optimize success and return for all participants.
Opportunity Access
Capitalize on access to innovative preclinical and early-stage clinical products and technology
Development Acceleration
Leverage an integrated ecosystem of development organizations and internal expertise to accelerate product development timelines
Business MONETIZATION
Monetize investments through strategic and well-timed out-licensing, sale or IPO of each product to provide liquidity to investors and the best path to bringing products to patients
Our process sounds simple but execution is where we excel
Acquire pipeline of differentiated products to meet underserved medical needs. If you think you have an innovation that fits our profile, contact us.
Deploy very experienced biopharma team for efficient drug development and business management
Utilize a successful organizational model; leverage virtual operations focused program management and partner ecosystem of service providers
Exit programs after advancing candidates to an appropriate value inflection point
Provide excellent returns to investors by delivering superior products to patients
MANAGEMENT TEAM
Ajit Gill
CEO and Founder, Director
CEO & President Nektar Therapeutics
VP and Gen Mgr Kodak’s Interactive Systems
VP Finance at TRW-Fujitsu
Steve Morris, MD
Head, Scientific Advisory Board
CEO & Internist/Medical Oncologist
Former PI: St Jude’s (discovered ALK, developed ALK CDx and inhibitors)
Michael Weickert, PhD
COO
CEO at Pacylex, Sonescence, SEA Med., COO Therashock, drug development at Ligand, Nektar, Auspex, NIH / NCI
Sanjeev Munshi, PHD, MBA
CBO
SVP, BD & Alliance Management, InveniAI
Ex. Director Merck BD and Discovery
Shailaja Gupta,PhD
Executive Director, CMC
Vikas Agarwal, PhD
VP Program Management
Gayathri Swaminath, PHD, MBA
VP Research
BOARD OF DIRECTORS
Purnanand Sarma, PhD
CEO Immunome
CEO Taris
GM Cephalon
VP Nektar
Ajit Gill
Director
Chris Searcy, Chief Corporate Development Officer
CBO Nocion
CBO Respira
CBO Taris
VP Valeritas, Nektar, Pfizer
Hong-Min Suh
Chair, M2N
CEO, DK Marine
Chair, The LEADCORP
Sangkeun (SK) Park
CEO Korea Solar
PIPELINE
Making a fast start to building an innovative pipeline, agnostic to therapeutic areas, we are addressing serious unmet medical needs.
If you think you have an innovation that fits this portfolio, contact us.
*Click for more information about portfolio candidates
| Product | Company | Target | Indication | Therapeutic Area | Discovery | Preclinical | Clinical | |||
|---|---|---|---|---|---|---|---|---|---|---|
| In Vitro | In vivo | Lead up | IND Enabling | Phase 1 | Phase 2 | |||||
| GRN-300 | Green3bio | SIK2/SIK3 inhibitor (First-in-Class) | Ovarian cancer, TNBC | Oncology | Q4 ‘23 Start | |||||
| PCLX-001 | Pacylex | NMT1, NMT2 inhibitor (First-in-class) | Diffuse Large B-Cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML) | Oncology | Q2 ‘23 Start | |||||
Questions? We’ve got answers!
Latest Articles
Greenfire Bio Portfolio Company Pacylex Pharmaceuticals Initiates Phase 1 Clinical Study of PCLX-001 in Non-Hodgkin’s Lymphomas and Solid Tumor Cancer Patients
First clinical patient dosed at Cross Cancer Institute, Edmonton, Alberta, Canada Dallas, TX, September 14, 2021 Greenfire Bio portfolio company Pacylex Pharmaceuticals, Inc. announced today that it initiated a Phase 1 clinical trial of PCLX-001, a first-in-class, orally bioavailable small...
Pacylex Pharmaceuticals Closes Series A Funding to Advance Oncology Program into the Clinic
Greenfire Bio Makes First External Investment Expanding Oncology Footprint Edmonton, Alberta, Canada, and Austin Texas, US, June 2, 2021 Pacylex Pharmaceuticals, an oncology company unlocking a new approach to cancer therapy, and Greenfire Bio, a new Life Science development and investment...
Greenfire Bio Announces Initiation of Phase 1 Clinical Trial of GRN-300, a SIK2 inhibitor, for Ovarian Cancer
Austin TX, January 15, 2021 -- Greenfire Bio, LLC announced today that its subsidiary, Green3Bio Inc., initiated a Phase 1 clinical trial of GRN-300, a first-in-class, orally bioavailable small molecule inhibitor of the Salt Inducible Kinases 2 and 3 (SIK2, SIK3), at the University of Texas MD...